II-III期非小细胞肺癌剂量递增放疗后食管毒性:ARTFORCE PET-Boost 2期随机试验二次分析
该二次分析基于ARTFORCE PET-Boost 2期随机试验,评估II-III期非小细胞肺癌患者接受剂量递增放疗后严重食管毒性的临床与剂量相关因素。107例患者中24例(22.4%)发生≥3级食管毒性,3例(2.8%)发生食管瘘相关死亡。试验中期引入食管+5mm剂量约束(D0.1%<70 Gy EQD2)后,≥3级食管毒性发生率从35.2%降至9.4%(P=.001)。多变量分析显示同步铂类双药化疗及食管高剂量与≥3级食管毒性独立相关。
要点
- 107例中24例(22.4%)发生≥3级食管毒性,3例(2.8%)食管瘘相关死亡。
- 试验中期引入D0.1%<70 Gy EQD2约束后,≥3级食管毒性从35.2%降至9.4%(P=.001)。
- 同步铂类双药化疗及食管高剂量(V50Gy、近最大剂量、等效均匀剂量)与≥3级食管毒性独立相关。
核心结论
- 同步铂类双药化疗及食管高剂量是严重食管毒性的独立相关因素,更严格的剂量约束显著降低了≥3级食管毒性发生率。
- 未来剂量递增研究应降低食管受量,尤其在联合同步化疗时(作者建议)。
研究设计与样本
- ARTFORCE PET-Boost试验(NCT01024829)的二次分析,随机纳入107例II-III期非小细胞肺癌患者。
- 患者接受24次3.0-5.4 Gy放疗,按等效生物剂量规划照射原发肿瘤整体(>4 cm)或18F-FDG-PET定义的原发肿瘤亚体积;淋巴结接受24×2.75 Gy。
- 放疗联合同步或序贯化疗,或单独放疗。
- 中位随访73.3个月(采用反向Kaplan-Meier法估算)。
主要发现
- 107例中24例(22.4%)发生≥3级食管毒性,3例(2.8%)发生食管瘘相关死亡。
- 食管中位平均剂量25.2 Gy(IQR 18.9-33.2),D0.1%(EQD2)中位69.5 Gy(IQR 66.4-75.4)。
- 试验中期引入食管+5 mm剂量约束(D0.1%<70 Gy EQD2)后,≥3级食管毒性发生率显著降低(19/54[35.2%] vs 5/53[9.4%];P=.001)。
- 多变量回归显示同步铂类双药化疗(对比同步每日低剂量顺铂或序贯/无化疗)及食管高剂量(V50Gy、近最大剂量、等效均匀剂量)与≥3级食管毒性显著相关。
关键数值与推荐
- 食管+5 mm剂量约束:D0.1%<70 Gy EQD2(试验中期引入)。
- ≥3级食管毒性发生率:约束引入前35.2%(19/54) vs 引入后9.4%(5/53),P=.001。
临床怎么用
- 未来剂量递增研究应降低食管受量,尤其在联合同步化疗时(作者建议)。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We previously reported unexpected high rates of severe esophageal toxicity (ET) in patients with stage II-III non-small cell lung cancer treated in the randomized ARTFORCE PET-Boost dose-escalation trial (clinicaltrials.gov: NCT01024829). The aim of this study is to evaluate clinical factors and dose metrics associated with ET in patients treated within the trial. METHODS AND MATERIALS: Patients received 24 fractions of 3.0-5.4 Gy, planned isotoxically to the primary tumor as a whole (>4 cm) or to an 18F-FDG-PET defined subvolume within the primary tumor. Lymph nodes received 24 × 2.75Gy. Radiation therapy was combined with concurrent or sequential chemotherapy, or given alone. We evaluated the incidence and time to grade ≥ 3 (G ≥ 3) ET, and patient-reported symptoms. Follow-up time was estimated using the reverse Kaplan-Meier method. Uni- and multivariable logistic regression analyses with Firth's penalization were performed to assess the associations between clinical variables, dose parameters, and the incidence of G ≥ 3 ET. RESULTS: Median follow-up was 73.3 months. Of 107 patients randomized, 24(22.4%) experienced G ≥ 3 ET. There were 3 (2.8%) ET-related deaths, all esophageal fistulas. Median esophagus mean dose and D0.1% (EQD2) were 25.2 Gy (IQR, 18.9-33.2), and 69.5Gy (IQR, 66.4-75.4), respectively. G ≥ 3 ET occurred less frequently (19/54[35.2%] vs 5/53[9.4%]; P = .001) after a dose constraint for esophagus + 5 mm was introduced mid-trial (D0.1% < 70 Gy EQD2). Concurrent platinum-doublet chemotherapy, (compared with concurrent daily low-dose cisplatin or sequential/no chemotherapy) and higher esophageal doses, especially volume receiving >50 Gy, near maximum doses, and the equivalent uniform dose, were significantly associated with G ≥ 3 ET in multivariable regression. CONCLUSIONS: Concurrent platinum-doublet chemotherapy, as well as high doses to the esophagus, was independently associated with risk of severe ET. Stricter dose constraints led to significant reduction in G ≥ 3 ET. Future dose-escalation studies should lower doses to the esophagus, especially when combined with concurrent chemotherapy.
引用
- Cooke SA, Belderbos JSA, Stam B, et al. Esophageal Toxicity After Dose-Escalated Radiation Therapy for Stage II-III Non-Small Cell Lung Cancer: A Secondary Analysis of the Phase 2 Randomized ARTFORCE PET-Boost Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 40156600. doi:10.1016/j.ijrobp.2025.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。